STOCK TITAN

Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) announced that Dr. Roger Jeffs, CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will be available via live webcast on Liquidia's website, with a replay and transcript archived for 30 days.
Positive
  • None.
Negative
  • None.

MORRISVILLE, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, beginning at approximately 11:15 a.m. Pacific Time (2:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.

Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia Technologies is also developing L606, an investigational liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, for use in North America. Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.

Contact Information

Media & Investors:
Jason Adair
Chief Business Officer
919.328.4400
jason.adair@liquidia.com 


FAQ

When is Dr. Roger Jeffs, CEO of Liquidia Corporation, presenting at the 42nd Annual J.P. Morgan Healthcare Conference?

Dr. Roger Jeffs will present on January 10, 2024.

Where will the presentation take place?

The presentation will be at the Westin St. Francis in San Francisco, California.

How can I access the live webcast of the presentation?

The live webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations.

Will there be a replay and transcript of the webcast available?

Yes, a replay and transcript will be archived on the Company's website for at least 30 days.

Liquidia Corporation

NASDAQ:LQDA

LQDA Rankings

LQDA Latest News

LQDA Stock Data

976.93M
49.94M
12.42%
51.22%
9.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
MORRISVILLE

About LQDA

liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.